Innovent Biologics’ shares surged 10% following a significant partnership with Pfizer to develop oncology medicines. The collaboration encompasses licensing, co-development, and co-commercialization of a portfolio featuring 12 early-stage cancer therapies. Innovent will lead four global programs, sharing development costs with Pfizer while retaining rights in Greater China. The deal includes an upfront payment of $650 million, with potential milestone payments totaling up to $10.5 billion, and double-digit royalties on approved products.

This partnership highlights a growing trend in the biotech sector, as pharmaceutical companies seek to fill pipeline gaps ahead of looming patent expirations. The focus on oncology is particularly relevant given the rising incidence of cancer globally, making this collaboration a strategic move for both companies.

For market professionals, the deal underscores the increasing value of strategic partnerships in the biotech space, particularly in oncology, and may signal further consolidation and collaboration as firms navigate upcoming patent cliffs.

Source: cnbc.com